Skip to main content
SpringerLink
Log in

Zoledronic acid treatment in advanced non-small cell lung cancer patients with bone metastases

  • Short Communication
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Bone metastases occur in 30–40 % of patients with advanced non-small cell lung cancer (NSCLC). Several studies have demonstrated the direct anticancer effect of zoledronic acid against lung cancer; however, most of these studies are preclinical research. A total of 311 NSCLC patients with bone metastases who were treated with zoledronic acid at Zhejiang Cancer Hospital between 2008 and 2011 were identified. Of these, 109 patients received zoledronic acid (4 mg intravenously every 21–28 days) more than 6 times (Group A), and the other 204 patients received zoledronic acid <6 times (Group B). All patients received standard chemotherapy and other treatments. Survival time was significantly longer in Group A than in Group B (385 vs. 275 days; P = 0.002), and the incidence of malignant pleural effusion was lower in Group A than in Group B (22.0 vs. 33.8 %; P = 0.041). In conclusion, our study results suggest that a longer zoledronic acid treatment period had a better effect on survival. Zoledronic acid use might decrease the incidence of malignant pleural effusion.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Ferlay J, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.

    Article  PubMed  CAS  Google Scholar 

  2. Ettinger DS, et al. Non-small cell lung cancer. J Natl Compr Cancer Netw. 2008;6:228–69.

    CAS  Google Scholar 

  3. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27:165–76.

    Article  PubMed  CAS  Google Scholar 

  4. De Marinis F, et al. Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel. J Thorac Oncol. 2009;4:1280–8.

    Article  PubMed  Google Scholar 

  5. Neville-Webbe HL, et al. Potential anticancer properties of bisphosphonates. Semin Oncol. 2010;37(Suppl 1):S53–65.

    Article  PubMed  CAS  Google Scholar 

  6. Gnanta M, et al. Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature. Cancer Treat Rev. 2012;38:407–15.

    Article  CAS  Google Scholar 

  7. Matsumoto S, et al. Efficacy of the third generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer lines. Lung Cancer. 2005;47:31–9.

    Article  PubMed  Google Scholar 

  8. Berger W, et al. (2005) The N-containing bisphosphonate zoledronic acid exerts potent anticancer activity against non-small cell lung cancer cells by inhibition of protein geranylgeranylation. Proc Am Assoc Cancer Res 46 (Abst 4981).

  9. Noguchi A, et al. Zoledronate-activated V γ 9γδT cell-based immunotherapy is feasible and restores the impairment of γδT cells in patients with solid tumors. Cytotherapy. 2011;13:92–7.

    Article  PubMed  CAS  Google Scholar 

  10. Zarogoulidis K, et al. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer. 2009;125:1705–9.

    Article  PubMed  CAS  Google Scholar 

  11. Stathopoulos GT, et al. Zoledronic acid is effective against experimental malignant pleural effusion. Am J Respir Crit Care Med. 2008;178:50–9.

    Article  PubMed  CAS  Google Scholar 

  12. Brown JE, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst. 2005;97:59–69.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Chemotherapy, Zhejiang Cancer Hospital, 38 Guangji Road, 310022, Hangzhou, People’s Republic of China

    Zhengbo Song & Yiping Zhang

  2. Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Hangzhou, 310022, Zhejiang Province, People’s Republic of China

    Zhengbo Song & Yiping Zhang

Authors
  1. Zhengbo Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yiping Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Zhengbo Song or Yiping Zhang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Song, Z., Zhang, Y. Zoledronic acid treatment in advanced non-small cell lung cancer patients with bone metastases. Med Oncol 31, 898 (2014). https://doi.org/10.1007/s12032-014-0898-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-014-0898-3

Keywords

Search

Navigation